Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | MME | P08473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27638949 | 0.83 | PLA2G2C (0.40) | PLA2G2CPMP22TSHRGAAKMT2A | |
| SCHEMBL5548951 | 0.83 | PLA2G2C (0.40) | PLA2G2CPMP22TSHRGAAKMT2A | |
| SCHEMBL14842028 | 0.81 | DNM1 (0.33) | DNM1 | |
| SCHEMBL15980600 | 0.77 | CA1 (0.40) | PLA2G2CGAAKMT2A | |
| SCHEMBL12225946 | 0.76 | PLA2G2C (0.33) | PLA2G2C | |
| SCHEMBL20186644 | 0.76 | DNM1 (0.43) | DNM1 | |
| SCHEMBL15152152 | 0.75 | — | — | |
| SCHEMBL5718023 | 0.74 | TSHR (0.39) | PLA2G2CPMP22TSHRGAAKMT2A | |
| SCHEMBL27638942 | 0.74 | PLA2G2C (0.35) | PLA2G2C | |
| SCHEMBL19285548 | 0.73 | GABRR1 (0.34) | KMT2ADNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2763976-B1 | 2-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK SHARP & DOHME (US) | 2016-05-18 | — | — | EP | disclosed |
| US-9216173-B2 | 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20140243336-A1 | 2-Pyridyl Carboxamide-Containing Spleen Tyrosine Kinase (SYK) Inhibitors | MERCK SHARP & DOHME LLC | 2014-08-28 | — | — | US | disclosed |
| EP-2763976-A1 | 2-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-08-13 | — | — | EP | disclosed |
| WO-2013052394-A1 | 2-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243336-A1 | 2-Pyridyl Carboxamide-Containing Spleen Tyrosine Kinase (SYK) Inhibitors | SYK, BTK, LCK | PLA2G2C 1918/4885PMP22 1144/4885TSHR 2620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.